

ALAPIS SA Company's Number in the Register of Societes Anonymes: 8057/06/E/R6/11 REGISTERED ADRESS: 2,AFTOKRATOROS NIKOLAOU STR, P.C 17671 ATHENS DATA AND INFORMATION FOR THE PERIOD 1 JANUARY 2009 TO 30 SEPTEMBER 2009 According to Decision 4/507/26,04.2009 of the Capital Market Committee the financial standing and the financial results of ALAPIS S.A. We, therefore, recommend the re alapis.eu, where all periodical financial statements under IFRS together with the Audit report of t COMPANY DEFAULS.

Website : Approval date for issuing by the Board of Directors STATEMENT OF FINANCIAL POSITION (amounts in tho ASSETS
Property, plant and equipment
Investment properties
Intangible assets
Other non current assets 30.09.2009 1.637.509 27.470 720.885 23.830 The Group 1.1. - 30.09.2009 1.1. - 30.09.2008 1.1. The Company 30.09.2009 1.1. - 30.09.2008 31.12.2008 1.524.905 Profits before taxes (continuous operation)
Profits before taxes (discontinuous operation
Plus/ less adjustments for: 140.680 (10.849) 125.661 3.539 97.571 (12.177) 75.539 (936) 45.399 (62) 1.456 (17) (2.560) 17.247 Other non-current assets
Irrade receivables
Other current assets
Non current assets available for sale 172.833 254.414 415.921 149.801 75.022 335.738 76.237 (103) 973 2.535 28.445 (30) (33) epreciation and amortization Sain) / Loss from disposal of tangible assets 50.652 79 (2.830) (4) 371 26.938 change differences sults (income, expenses, gain, loss) from investing activity erest expense (11.231) 9.216 (1.002) 44.977 TOTAL ASSETS 3.252.862 2.832.174 3.024.617 2.454.889 leQUITY AND LIABILITIES
Share capital
Other equity items
Total owners' equity o,
Non controlling interests (b)
Total equity (c) = (a) * (b)
Long term borrowings
Provisions' Other long term liabilities
Short-term borrowings /less changes in working capital: (24.702) (157.385) 24.868 ecrease / (increase) of inventories (11.830) 1.429.288 2.017.648 (198.298) 16.625 (58.312) (73.237) 3.333 1.543.001 2.000.125 2.017.648 1.528.32 700.000 152.001 57.979 342.757 702.606 122.788 169.459 294.319 700.000 60.110 50.000 196.859 664.843 49.001 135.430 77.292 ecrease) / Increase of trade liabilities (excluding borrowings) 1.285 22.397 11.394 (25.146) (5.203) 76.270 (4.457) 7.825 Short-term borrowings Other short term liabilities Non current liabilities available for sale Less:
Interest paid
Taxes paid
Operating cash flow from discontinued operation
Net cash flows from operating activities (a) (51.689) (16.064) (31.342) 1.252.737 1.289.172 Total liabilities (d) 1.006.969 TOTAL EQUITY AND LIABILITIES (c)+(d) 3.252.862 2.832.174 3.024.617 2.454.889 cquisition)/Disposal of subsidiaries, related, joint ventures and other investmen (119.449) (42.932) (178.707) 21.62 (297.654) 3.567 9.123 (246.795) 3.113 9.123 (178.094) 1.062 (54.490) 691 0 urchase)/Disposal of tangible and intangible assets erest received 1.1. - 30.09.2009 1.1. - 30.09.2008 Discontioceeds from dividents Proceeds from grants / Guarantees paid nvesting cash flow form discontinued operation let cash flows from investing activities (b) (212.917 Gross profit/(loss)
Profit before tax, financial and investing results (EBIT)
Profit/(loss) before tax
Profit/(loss) (a) Financing activities Financing activities
Issue of share capital
Proceeds from borrowings
Payments of borrowings
Proceeds / (payments) of finance lease obligations
Dividents paid
Treasury shares
Gain from disposal of share capital's issue rights
Financina activities from discontinued operation 423.063 87.557 (137.830) (220) (9.998) 423.063 95.857 (210.622) 15.826 (10.125) wners of the parent (6.538) (6.360) (24.675) (34.432) 101.279 (222) 103.772 112.242 (428) 105.704 (428) 2.494 4.006 4.006 ther comprehensive income (net of tax) (b) otal comprehensive income (net of tax) (a) + (b) (24.017) 87.797 (24.017) 81.259 (557) 100.499 (6.538) Financing activities from discontinued operation Net cash flows from financing activities (c) 318,005 366.579 89.288 165.985 wners of the parent lon-controlling interes 88.227 (430) (6.538) 81.689 (430) 100.707 (208) 2.494 103.20 Net increase in cash and cash equivalents (a)+(b)+(c) (197.132) (88.252 Net profit per share - basic (in€) Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA) Cash and cash equivalents at beginning of the period Cash and cash equivalents of mergers Cash and cash equivalents at end of the period 318.023 163.168 0,1206 260.892 0,1136 251.688 0,1037 185.746 0,0026 4.970 208.679 121.305 (0,0070) (9.204) 312.317 120.891 74.916 - 30.09.2009 - 30.09.2008 STATEMENT OF CHANGES IN EQUITY (amounts in thousands€) Continuing 246.654 98.874 57.280 42.318 32.075 The Group
1.1. - 30.09.2009
1.1. - 30.09.2008
1.543.001
1.609.057
81.259
2.175
85 The Company
1.1. - 30.09.2009 1.1. - 30.09.2008
1.528.323 1.608.043
45.698 59.211 Equity balance at the beginning of the period (1.1.2009 and 1.1.2008 respectively)
Total comprehensive income (net of tax) (continuing and discontinued operations)
Sale of subsidiaries ofit/(loss) (a) (24.515) (24.515 ners of the paren 32.070 (2.440) 29.630 31.946 (42) 896 0 32.841 478 (34.432) Acquisition of subsidiaries
Purchase of treasury shares
Merger of subsidiaries
Equity balance at the end of the period (30.09.2009 and 30.09.2008 respectively
ADDITIONAL DATA AND INFORMATION (continuation)

ADDITIONAL DATA AND INFORMATION (continuation) (34.432 2.550 Other comprehensive income (net of tax) (t Total comprehensive income (net of tax) (a) + (t (24.234) 7.841 (24.234) 5.401 (217) 31.687 2.000.125 1.653.665 1.608.30 distribute, export and trade the aforementioned products and the company with the distribute to trade the aforementioned products.

3. The financial statements of the Company are not included in consolidated financial statements of any other company.

4. There are no litigation matters which may have material impact on the financial position of the Group and the Company. The amount of the provisions for any litigation matters on 3.0.09.2009 amounts to £1.78.71 for the Group and £6.78.78 for the Group and £6.78 for the Group and the Company thave made no other provisions.

5. The number of employees at the end of current period for the Group and the Company is 2.917 and 781 respectively and for the period ended on 30.09.2008 was 1.730 and 252 for the Group and the Company respectively ners of the parent 7.836 5 (2.440) 5.396 5 31.714 (28) 896 0 Net profit per share - basic (in€) Profit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA) 0,0330 85.480 0.0305 0,0330 62.877 (0,0025) (4.836) 0,0009 1.814 64.691 80.644 The Company - 30.09.2009 9.2008 Continuing 6. Within the course of the first quarter of 2009 the Group management decided to the disinvestment of the organic sector and to proceed immediately with a) closure of the retail stores under the name Viologikos Kiklos b) cease of production and distribution of organic products (Egil of disposal or liquidation procedure for the companies activated in the dission of organic products (Egil of Scandings) this segment is presented at the current financial statements as discontinued operation according to IFIRS 5 and some of the amounts of the previous financial statements were reclassified in orded to become comparable to those of the current period. Further analysis is quoted in the note 17 of the current financial statements and the second of the current period for the current period. Further analysis is quoted in the note 17 of the current for the current period for the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 of the current period. Further analysis is quoted in the note 17 o 289.356 176.354 112.703 85.394 69.705 operations operations Gross profit/(loss)
Profit before tax, finan
Profit/(loss) before tax
Profit/(loss) (a) (381) (8.727) (12.177) (9.365) 73.524 75.539 **60.014** (936) (936) (702) 97.571 **79.070** 292 5.754 17.672 3.010 1.200 COMPANY 208.013 102.561 79.070 0 b) Expenses:
5,754 102.bb1
c) Receivables:
7,754 102.bb1
c) Receivables:
9,10 abilities:
17,872 302.575
d) Labilities:
18,800 1,800 (24.007) 55.063 (101) 59.913 (24.007) 45.698 (9.365) (702) 55.063 (9.365) Net profit per share - basic (in€)
---fil/face\ hefore tax financial, investing results, depreciation and amortisation (EBITDA) 0,0850 172.082 The Company - 30.09.2008 scontinued ANIMAL HEALTH S.A. are fully consolidated to the Group for the first time in the current period. The aforementioned companies were acquired or established during the current period and are consolidated than financial statements of ALAPIS SA since their acquisition or establishment date. The consolidated financial statements for the period ended September 30, 2009, do not include the balance sheet Information of CILIKEIA (GEIS SA, GLIKEIA GEFSI SA, PROIONTA EBIK SA, CERTIFIED ORGANIC PRODUCTS LTD, THERAPETTIKI SA, EBIK SA and LYD SA which were sold during the current period. MEDIMEC SA is fully consolidated to the Group since 29,5,2009 due to the completion of the acquisition approval by the Competition Commission, while on 31,3,2009 was consolidated applying the equity method. During the forth quater of 2008 the merger benefor proper to company in a basoppina with its subsidiaries LANDA APPLIED SA and LAPIS SA was approved. JALAPIS CROPSCIENCE SA, REVOLD SA, PHARMALEX SA and BIODOMUS SA was concluded the nemegra of the parent company via absorption with its subsidiaries LANDA APPLIED SA and LAPIS PHARMAS AWAS aspaproved, pursuant to the provisions of CL 1980/20 and L. 1266/1939. Furthermore, BIOCHEM DIAGNOSTICS SA merged the 100% subsidiaries of ALAPIS SA, OMIKRON MEDICAL SA and LABOMED SA by naming the company JALAPIS MEDICAL SA. DIAGNOSTICS SA, in accordance with the sitipulations of the articles of Cod. Law 1910/1942 and Law 2166/1939. Trially, or 33.2 9.0009 pursuant to the 23.9.2009 pursuant to the decision No. 13399/15.09.2009 of the Thessalonica Prefecture, was concluded the merger of ALAPIS subsidiary PHARMAGORA SA with its 100% subsidiary SANTE HELLAS SA, by the absorption of the second from the first, in accordance with the stipulations of the articles of Cod. Law 1910/1942 and Law 2166/1939.

11.13.00.9.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 1.1.30.09.2009 Continuing Continuing operations operations 93 337 54.325 26.817 19.642 12.547 54.325 22.163 11.539 **6.244** 50.117 28.930 23.536 16.037 (251) (312) (312) (234) (4.654) (8.104) (6.303) 23.224 15.803 12.547 (6.303) 16.037 (234) 6.244 (24.007) (11.460) (24.007) (17.762) (34) 16.003 (34 15.76 (6.303) (234) COMPANY 1.1-30.09.2009 1.1-30.09.2008 | Currency translation differences | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1-3.0.9.2009 | 1.1 16.003 (6.303) et profit per share - basic (in€) rofit/(loss) before tax, financial, investing results, depreciation and amortisation (EBITDA) 0,0129 43.730 0,0166 39.062 ADDITIONAL DATA AND INFORMATION ADDITIONAL DATA AND INFORMATION

1. The companies included in the consolidated financial statements, together with their registered addressess, the consolidation method in the financial statements of the Company and their share of participation are analyzed in note 5 of the financial statements and the tax unaudited FYs of the companies are analyzed in note 14 of the financial statements.

2. Until the nine month period ended 30 September 2009, ALAPIS SA stablished and acquired the companies mentioned back and PNG GEROLYMATOS MEDICAL SA respectively as well as 40% stake and 1% stake in ASNETA SEAS CHRISTOFOCLOU SA and PHARMASOF IT ID following which ALAPIS SA now controls 100% of the share capitals of the companies mentioned above. The Company also proceeded with the acquisition of the 35,20% stake of the company IPIROPHARM SA and the 1,88% of SUMADIJALEK SA following which ALAPIS SA now controls 100% of the share capital of these companies mentioned above. The Company also proceeded with the acquisition of 100% of the company IPIROPHARM SA and the 1,88% of SUMADIJALEK SA following which ALAPIS SA now controls 1,20% and 97,79% of the share capital of these companies respectively. On March 30, 2009, the Company proceeded with the acquisition of 100% of the company IPIROPHARM SA which represents which represents which represents well on the orthopedic material sector and controls 40% of the company MEDIMEC SA. Furthermore.until 29.5.2009 the Company proceeded with the acquisition of 100% of the company IPIROPHARM SA which represents well known brands in the orthopedic material sector and controls 40% of the company IPIROPHARM SA which represents well known brands in the orthopedic material sector and controls 40% of the company IPIROPHARM SA which represents well known brands in the orthopedic material sector and controls 40% of the company IPIROPHARM SA which represents well known brands in the company intended with the acquisition of 100% of the company IPIROPHARM SA which represents well known brands in the co

calance sheet date (financial statements) 3.05.2009. Furthermore, within 2009 the activity regarding detergent products of the company JALL SX will be absorbed by the parent company JALPIS AA. 13. The Board of Directors of Alapis SA. announces that the rights issue offered to existing shareholders by means of pre-emption rights, which was decided on 5.8 2009 by it and took place from 4.9.2009 until 18.9.2009, has been fully subscribed with a payment of a total amount of 451.076.101.20 euros and the issuance of 980.600.220 new, common, dematerialised and registered voting shares, each having a nominal value of 0.30 euro and a subscription price of 0.46 euro. The total amount of shares requested by those who exercised the pre-emption rights and those who exercised the oversubscription rights oversubscribed the share capital increase 1,752 times. In light of the above, the share capital of the company has been increased to 294.180.066 euros with the issuance and distribution of 990.600.220 new, common, dematerialised and registered voting shares, each having a nominal value of 0.30 euro. The difference between the nominal value of the shares and the subscription price of the shares amounting in total to 156.896.035 euros was credited, after the deduction of the expenses in respect of the right is sue, to the account. Share Premium Account Excess Over par Value of Shares Issued. The trading of new shares commenced on 25.09.2009.

14. On 29.10.2009.ALAPIS SA announced the establishment of the company SAMBROOK MED SA whose core objective is the production of pharmaceutical, parapharmaceutical and cosmetic products, the company SAMBROOK MED SA whose core objective is the production of pharmaceutical (numan and veterinary), parapharmaceutical and cosmetic products, the company SAMBROOK MED SA whose core objective is the production of pharmaceutical (numan and veterinary), parapharmaceutical (OTC) products and det foods and the establishment of the company SAMBROOK, whose core objective is the trade and improof tabloxy,